



Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium

February 7, 2019

Company to Highlight ARV-110 PROTAC™ Protein Degradator for the Treatment of Prostate Cancer

NEW HAVEN, Conn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present a poster at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in San Francisco. The presentation will highlight the company's lead product candidate, ARV-110, an oral androgen receptor (AR)-targeted PROTAC™ (Proteolysis-Targeting Chimera) protein degrader for the treatment of men with metastatic castration-resistant prostate cancer. ARV-110 employs Arvinas' proprietary PROTAC protein degradation technology.

Presentation details are as follows:

Title: *ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.*
Abstract Number: 259
Poster: L16
Session Information: Poster Session A: Prostate Cancer
Session Date/Time: February 14; 11:30 a.m. - 1:00 p.m.; 5:30 – 6:30 p.m.

All abstracts for the Symposium will be released by ASCO on February 11, 2019 at 5:00 p.m. EST on meetinglibrary.asco.org.

About ARV-110

ARV-110 is an orally-bioavailable PROTAC protein degrader designed to selectively target and degrade androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). ARV-110 has demonstrated promising activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. Arvinas believes the differentiated pharmacology of ARV-110, including its iterative activity, has the potential to translate into improved clinical outcomes for patients.

About Arvinas

Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body's own natural protein recycling system to selectively and efficiently degrade and remove disease-causing proteins. For more information, see www.arvinas.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, including the timing of our clinical trial for ARV-110. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully initiate a Phase 1 clinical trial for ARV-110 and complete our clinical trials for our product candidates on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements our expected timeline and other important factors discussed in the "Risk Factors" sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

Contacts for Arvinas

Investors

Randy Teel, VP Corporate Development
ir@arvinas.com

Media

Cory Tromblee, ScientPR
pr@arvinas.com



Source: Arvinas Inc.